For sufferers with early-stage breast cancer, 10-year outcomes are similar for treatment with partial breast irradiation (PBI), and whole breast irradiation (WBI), based on a study explained at the annual San Antonio Breast Cancer Symposium, held from December 10 to 14 in Texas.
Icro Meattini, M.D., from the Florence University, Italy, and colleagues presented 10-year follow-up data from the APBI IMRT Florence section 3 trial. Women aged older than 40 years affected by early breast cancer had been randomly assigned to obtain either WBI utilizing three-dimensional conformal radiotherapy or accelerated PBI using a depth-modulated radiotherapy technique. 260 patients have been enrolled in each arm.
The researchers found no significant difference in terms of ipsilateral breast tumor recurrence (IBTR) rates between the therapy arms (log-rank test, P = 0.58). The five-year and 10-year IBTR rates had been 1.96% and 3.74% (9 times; 95% CI, 1.5 to 6.3), respectively, in the APBI group in contrast with 1.2% (3 times; 95% CI, 0 to 2.5) and 2.5% (6 times; 95% CI, 0.7 to 4.5), for the WBI group.
For APBI versus WBI sufferers, the risk ratio was 1.33 (95% confidence interval, 0.49 to 3.56; P = 0.58). Regarding survival outcomes, there have been no critical variations observed between the treatment arms (overall survival, 95.4% in APBI against 94.3% in WBI; risk ratio, 0.66; 95% confidence interval, 0.29 to 1.53; P = 0.33).